Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma.
Mona Amini-AdleN KhanaferM Le-BouarG DuruS DalleL ThomasPublished in: BMC cancer (2018)
This is the largest series of unselected patients treated in real-life with anti-PD-1 as second-or-higher line of treatment. Anti-PD-1 was less effective in BRAF-mutated cases as a majority of patients presented aggressive tumor evolution after BRAFi discontinuation. These data are consistent with previous studies suggesting a negative impact of BRAFi prior to immunotherapy.